Opus Bank’s Merchant Banking division served as financial advisor to ProPharma Group Holdings in its sale to Linden Capital Partners.

“We are excited to partner with Linden. Their healthcare expertise and proven track record makes them the right partner as we embark on the next phase of our growth strategy,” Jeff Hargroves, founder, chief executive officer and president of ProPharma Group said. “Linden understands our culture, market and customers and can support our company with both organic growth and acquisition initiatives.”

Paul Kacik, managing director and head of Healthcare Merchant Banking at Opus Financial Partners added, “ProPharma Group has a long-standing history of providing a uniquely differentiated and comprehensive suite of services for clients in the pharmaceutical and life sciences industries. We are very pleased to have had the opportunity to work with the ProPharma team and guide them through this important milestone. We look forward to following Jeff Hargroves and the entire ProPharma Group management team as they partner with an exceptional group of operating and investment professionals at Linden and continue to grow and realize their long-term vision for the company.”

ProPharma Group is a provider of medical information, pharmacovigilance and compliance consulting services to clients in the pharmaceutical, biotechnology and medical device industries.

Opus Bank has $7.7 billion of total assets, $6.3 billion of total loans and $6.5 billion in total deposits, as of September 30, 2016. Opus Bank’s Merchant Banking division provides direct investment and advisory solutions to lower middle-market companies.

Linden Capital Partners is a Chicago-based private equity firm focused on leveraged buyouts in the healthcare and life science industries.